Semin Thromb Hemost 2023; 49(03): 234-241
DOI: 10.1055/s-0042-1758060
Review Article

Hemostasis from Bench to Bedside: The History of Three Successful Stories of Translational Medicine

Armando Tripodi
1   Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Luigi Villa, Milano, Italy
› Author Affiliations

Abstract

Looking at the history of hemostasis, one can easily conclude that most of the achievements we see today have been done through the ingenuity and dedication of scientists, who devoted their efforts to translate the basic concepts behind their hypotheses from the laboratory to the patient bedside. I am personally excited by three of these stories. This article aims to review the history on the development of D-dimer, heparin, and coagulometers, which have been chosen as paradigmatic examples of diagnostic testing, drugs, and measuring devices, respectively. They should be considered among the most successful histories of translational medicine.



Publication History

Article published online:
17 October 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Gaffney PJ. Distinction between fibrinogen and fibrin degradation products in plasma. Clin Chim Acta 1975; 65 (01) 109-115
  • 2 Rylatt DB, Blake AS, Cottis LE. et al. An immunoassay for human D dimer using monoclonal antibodies. Thromb Res 1983; 31 (06) 767-778
  • 3 Elms MJ, Bunce IH, Bundesen PG. et al. Rapid detection of cross-linked fibrin degradation products in plasma using monoclonal antibody-coated latex particles. Am J Clin Pathol 1986; 85 (03) 360-364
  • 4 Bounameaux H, Cirafici P, de Moerloose P. et al. Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism. Lancet 1991; 337 (8735): 196-200
  • 5 Wells PS, Anderson DR, Bormanis J. et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997; 350 (9094): 1795-1798
  • 6 Wells PS. Integrated strategies for the diagnosis of venous thromboembolism. J Thromb Haemost 2007; 5 (Suppl. 01) 41-50
  • 7 van Belle A, Büller HR, Huisman MV. et al; Christopher Study Investigators. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006; 295 (02) 172-179
  • 8 Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87 (01) 7-12
  • 9 Verhovsek M, Douketis JD, Yi Q. et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149 (07) 481-490 , W94
  • 10 Palareti G, Cosmi B, Legnani C. et al; PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355 (17) 1780-1789
  • 11 Taylor Jr FB, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86 (05) 1327-1330
  • 12 Lowe GD. Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture. Br J Haematol 2006; 133 (03) 232-250
  • 13 Kline JA, Williams GW, Hernandez-Nino J. D-dimer concentrations in normal pregnancy: new diagnostic thresholds are needed. Clin Chem 2005; 51 (05) 825-829
  • 14 Wu C, Chen X, Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180 (07) 934-943
  • 15 Lippi G, Tripodi A, Simundic AM, Favaloro EJ. International survey on D-dimer test reporting: a call for standardization. Semin Thromb Hemost 2015; 41 (03) 287-293
  • 16 Barrowcliffe TW. Heparin, a Century of Progress. Berlin Heidelberg: Springer Verlag; 2012: 3-22
  • 17 Charles AF, Scott DA. Studies on heparin: observations on the chemistry of heparin. Biochem J 1936; 30 (10) 1927-1933
  • 18 Murray DW, Jaques LB, Perrett TS, Best CH. Heparin and vascular occlusion. Can Med Assoc J 1936; 35 (06) 621-622
  • 19 Best CH, Cowan C, Maclean DL. Heparin and the formation of white thrombi. Science 1937; 85 (2205): 338-339
  • 20 Best CH. Heparin and thrombosis. BMJ 1938; 2 (4062): 977-1004.1
  • 21 Best CH, Cowan C, Maclean DL. Heparin and the formation of white thrombi. J Physiol 1938; 92 (01) 20-31
  • 22 Murray GD, Best CH. The use of heparin in thrombosis. Ann Surg 1938; 108 (02) 163-177
  • 23 Kakkar VV, Field ES, Nicolaides AN, Flute PT. Low doses of heparin in prevention of deep-vein thrombosis. Lancet 1971; 2 (7726): 669-671
  • 24 Abildgaard U. Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest 1968; 21 (01) 89-91
  • 25 Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69 (02) 570-577
  • 26 Choay J, Petitou M, Lormeau JC, Sinaÿ P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116 (02) 492-499
  • 27 Thunberg L, Bäckström G, Lindahl U. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res 1982; 100: 393-410
  • 28 Choay J, Lormeau JC, Petitou M, Sinaÿ P, Fareed J. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann N Y Acad Sci 1981; 370: 644-649
  • 29 Casu B, Oreste P, Torri G. et al. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J 1981; 197 (03) 599-609
  • 30 Yin ET, Wessler S, Stoll PJ. Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor. J Biol Chem 1971; 246 (11) 3712-3719
  • 31 Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. Br Med J (Clin Res Ed) 1982; 284 (6313): 375-379
  • 32 Ciavarella N, Eder G, Mannucci PM. et al; Italian CISMEL Study Group. Multicentre comparison of nine coagulometers and manual tilt-tube methods for prothrombin time performance. Clin Lab Haematol 1983; 5 (02) 177-184
  • 33 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530
  • 34 Chantarangkul V, Tripodi A, Mannucci PM. Evaluation of a fully automated centrifugal analyzer for performance of hemostasis tests. Clin Chem 1987; 33 (10) 1888-1890